24% P<0.0001 REDUCTION in
primary end point with ivabradine1
17% P=0.0166 REDUCTION in
cardiovascular death with ivabradine

SITE SHIFT 02

Ivabradine or placebo on top of guideline-recommended therapy including ACE
inhibitor, β-blocker, mineralocorticoi receptor antagonist.

17% P=0.0109 REDUCTION in all-cause death with ivabradine
39% P=0.0006 REDUCTION in death from heart failure


1. Böhm M, et al. Clin Res Cardiol. 2013;102(1):11-22.

you want to know more …

on the impact of elevated heart rate on the primary outcomes

The greater the heart rate reduction (≥10 bpm or heart rate <60 bpm at 28 days), the lower the primary end point event rate whatever the baseline heart rate.1

SITE SHIFT 02